CBS 2019
CBSMD教育中心
中 文

DAPT Duration

Abstract

Recommended Article

Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial Ticagrelor versus clopidogrel in patients with acute coronary syndromes Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial 'Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trial

Original Research

JOURNAL:CBSMD Article Link

医疗机构及临床医生应如何设置与解读Hs-cTn?

CBSMD

Pre-reading

高敏肌钙蛋白I或T检测(hs-cTnI/T)已在全球推广开来, “Recommendations for Institutions Transitioning to  High-Sensitivity Troponin Testing: JACC Scientific Expert Panel”可谓hs-cTn百科全书, 从医疗机构到临床医生、从急诊到住院、从心肌梗死到排除诊断,多角度地介绍了医疗机构如何在日常临床中实现从cTn检测到hs-cTn检测的过渡,指出了该过程中所涉及的实验室、临床诊疗中的技术细节。欢迎各位专家访问CBS Scientific Library-右侧文献进一步阅览原文,以下为其中的关键点:



医疗机构实验室应如何实现从cTn检测过渡到hs-cTn检测:

1. 实验室专家应对阈值的选择做出谨慎的考量,对于肌钙蛋白而言,第99百分位作为健康人群的公认阈值上限,等于或低于此阈值会增加肌钙蛋白假阳性结果,此阈值已被纳入《第四版心肌梗死通用定义》中。

2. 敏感度

(1) hs-cTn是可实现在心肌梗死发作短时间内检测到心肌损伤的高敏指标, 相对于cTn检测,hs-cTn检测进一步优化了信噪比(signal-to-noise ratio);

(2) hs-cTn检测的高敏感度体现在男性和女性患者不同的检测阈值上;

(3) 实验室负责人对hs-cTn的选择应基于现有cTn检测仪器的类别;因缺乏足够的数据支持,现阶段不建议推行床旁hs-cTn检测(point-of-care hs-cTn);

(4) 建议一家机构不兼用hs-cTn和cTn检测,不同科室间应统一一种检测法;

(5) Hs-cTn总检测时长应控制在60分钟之内;

(6) 为方便解读检测结果,建议hs-cTnI/T的单位应设为纳克/升,如25ng/l。



临床医生应结合患者的临床表现hs-cTnI/T检测结果做出不同鉴别诊断,临床决策可参考以下建议:

(1) hs-cTn 升高所涉及的鉴别诊断;

(2) hs-cTn不同水平及其诊断可能;

(3) 使用hs-cTn在不同时间窗内的测量值进行的排除诊断;

(4) 如何将hs-cTn结合其他诊断手段明确急性胸痛患者的收治;

(5) 如何使用hs-cTn指导非介入检查;

(6) hs-cTn在不同临床科室、不同疾病中的解读。